SIMILAR PATTERNS OF AMINO ACIDS FOR 3CS9_A_NILA600_2

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 428 LEU A 457 THR A 474 GLY A 480 PHE A 517 HIS A 519 LEU A 528	None	0.66A	3cs9A-1k2pA: 25.6	3cs9A-1k2pA: 45.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	ALA A 220 GLU A 236 MET A 240 LEU A 248 THR A 266 GLY A 272 HIS A 312 LEU A 321	None	0.60A	3cs9A-1k9aA: 31.2	3cs9A-1k9aA: 31.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	ALA A 220 GLU A 236 VAL A 239 MET A 240 THR A 266 GLY A 272 HIS A 312 LEU A 321	None	0.62A	3cs9A-1k9aA: 31.2	3cs9A-1k9aA: 31.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	6	ALA A 606 GLY A 660 PHE A 720 HIS A 722 LEU A 731 ALA A 741	None	0.60A	3cs9A-1lufA: 35.4	3cs9A-1lufA: 37.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	10	ALA A 288 GLU A 305 VAL A 308 MET A 309 LEU A 317 THR A 334 GLY A 340 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) None P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.59A	3cs9A-1opkA: 34.8	3cs9A-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	10	GLU A 305 VAL A 308 MET A 309 ILE A 312 LEU A 317 THR A 334 GLY A 340 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-4.2A) None P16 A 2 (-3.3A) None None P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.70A	3cs9A-1opkA: 34.8	3cs9A-1opkA: 57.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	5	ALA A 230 GLY A 286 HIS A 331 LEU A 340 ALA A 350	PY1 A 700 (-3.5A) PY1 A 700 (-3.6A) None PY1 A 700 (-4.4A) PY1 A 700 ( 4.2A)	0.39A	3cs9A-1py5A: 26.0	3cs9A-1py5A: 27.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 389 LEU A 418 GLY A 441 HIS A 480 LEU A 489	None	0.41A	3cs9A-1snxA: 22.5	3cs9A-1snxA: 41.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 621 GLU A 640 VAL A 643 THR A 670 GLY A 676 HIS A 790 LEU A 799	STI A 3 (-3.5A) STI A 3 (-3.6A) None STI A 3 (-3.2A) STI A 3 ( 3.8A) STI A 3 (-4.5A) STI A 3 (-4.4A)	0.50A	3cs9A-1t46A: 34.7	3cs9A-1t46A: 37.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 367 GLU A 386 MET A 390 GLY A 420 HIS A 459 LEU A 468	STU A 100 (-3.2A) None None STU A 100 (-3.5A) None STU A 100 (-4.5A)	0.64A	3cs9A-1u59A: 30.7	3cs9A-1u59A: 38.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2buj	SERINE/THREONINE-PRO TEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 47 GLU A 65 GLY A 104 HIS A 146 LEU A 155	STU A1301 (-3.6A) None STU A1301 ( 4.0A) None STU A1301 ( 4.8A)	0.43A	3cs9A-2bujA: 23.0	3cs9A-2bujA: 23.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA X 37 GLU X 54 MET X 58 LEU X 66 THR X 82 GLY X 88 LEU X 137 ALA X 147	STU X 902 (-3.1A) STU X 902 ( 4.4A) None None STU X 902 (-4.1A) STU X 902 (-3.5A) STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.71A	3cs9A-2dq7X: 32.3	3cs9A-2dq7X: 45.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA X 37 MET X 58 LEU X 66 THR X 82 GLY X 88 HIS X 128 LEU X 137 ALA X 147	STU X 902 (-3.1A) None None STU X 902 (-4.1A) STU X 902 (-3.5A) None STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.59A	3cs9A-2dq7X: 32.3	3cs9A-2dq7X: 45.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 184 GLU A 201 VAL A 204 GLY A 240 LEU A 290 ALA A 319	None	1.17A	3cs9A-2eu9A: 21.4	3cs9A-2eu9A: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 184 GLU A 201 VAL A 204 ILE A 208 LEU A 290 ALA A 319	None	0.91A	3cs9A-2eu9A: 21.4	3cs9A-2eu9A: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	ALA A 293 LEU A 322 THR A 338 GLY A 344 HIS A 384 LEU A 393 ALA A 403	H8H A 534 (-3.2A) None H8H A 534 (-3.1A) H8H A 534 (-3.3A) None H8H A 534 (-4.5A) H8H A 534 ( 4.0A)	0.59A	3cs9A-2h8hA: 30.7	3cs9A-2h8hA: 27.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 293 LEU A 322 GLY A 344 HIS A 384 LEU A 393 ALA A 403	QUE A 1 (-3.5A) None QUE A 1 (-3.0A) None QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	0.45A	3cs9A-2hckA: 30.2	3cs9A-2hckA: 30.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 293 LEU A 322 THR A 338 GLY A 344 LEU A 393 ALA A 403	QUE A 1 (-3.5A) None QUE A 1 (-3.3A) QUE A 1 (-3.0A) QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	0.58A	3cs9A-2hckA: 30.2	3cs9A-2hckA: 30.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 271 GLU A 288 VAL A 291 MET A 292 LEU A 300 THR A 316	1BM A 499 (-3.6A) 1BM A 499 (-3.2A) None 1BM A 499 ( 3.8A) None 1BM A 499 (-3.2A)	0.57A	3cs9A-2hk5A: 27.5	3cs9A-2hk5A: 48.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	ALA A 271 VAL A 291 MET A 292 LEU A 300 THR A 316 GLY A 322 HIS A 362 LEU A 371 ALA A 381	1BM A 499 (-3.6A) None 1BM A 499 ( 3.8A) None 1BM A 499 (-3.2A) 1BM A 499 (-3.5A) None 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A)	0.64A	3cs9A-2hk5A: 27.5	3cs9A-2hk5A: 48.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	ALA A 269 GLU A 286 VAL A 289 MET A 290 ILE A 293 LEU A 298 THR A 315 GLY A 321 LEU A 370 ALA A 380	GIN A 600 (-3.1A) GIN A 600 (-3.6A) None GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.2A) GIN A 600 (-3.4A) None GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.57A	3cs9A-2hz0A: 35.0	3cs9A-2hz0A: 98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 289 MET A 290 ILE A 293 LEU A 298 THR A 315 GLY A 321 HIS A 361 LEU A 370 ALA A 380	None GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.2A) GIN A 600 (-3.4A) None GIN A 600 (-4.3A) GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.72A	3cs9A-2hz0A: 35.0	3cs9A-2hz0A: 98.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	7	ALA A 452 GLU A 471 MET A 475 GLY A 505 PHE A 542 HIS A 544 LEU A 553	4ST A1687 (-3.3A) 4ST A1687 ( 4.6A) None 4ST A1687 (-3.2A) None None 4ST A1687 (-4.4A)	0.69A	3cs9A-2j0jA: 32.7	3cs9A-2j0jA: 20.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ALA A 452 MET A 475 GLY A 505 PHE A 542 HIS A 544 LEU A 553	BII A1687 (-3.5A) None BII A1687 (-3.6A) None None BII A1687 (-4.2A)	0.66A	3cs9A-2jkmA: 32.5	3cs9A-2jkmA: 40.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	ALA A 271 GLU A 288 MET A 292 LEU A 300 THR A 316 GLY A 322 HIS A 362 LEU A 371 ALA A 381	1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.9A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.5A) None 1N8 A 501 ( 4.3A) 1N8 A 501 ( 3.3A)	0.46A	3cs9A-2og8A: 32.4	3cs9A-2og8A: 47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 614 GLU A 633 MET A 637 THR A 663 GLY A 669 HIS A 776 LEU A 785	None	0.72A	3cs9A-2ogvA: 32.7	3cs9A-2ogvA: 38.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 853 VAL A 875 GLY A 908 HIS A 962 LEU A 971 ALA A 981	MR9 A 301 (-3.5A) MR9 A 301 ( 4.8A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A)	0.40A	3cs9A-2p4iA: 23.9	3cs9A-2p4iA: 37.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 515 GLU A 534 MET A 538 ILE A 541 GLY A 570 LEU A 633 ALA A 643	None	0.71A	3cs9A-2psqA: 32.5	3cs9A-2psqA: 35.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 515 MET A 538 ILE A 541 GLY A 570 HIS A 624 LEU A 633 ALA A 643	None	0.58A	3cs9A-2psqA: 32.5	3cs9A-2psqA: 35.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 215 ILE A 233 THR A 265 HIS A 319 LEU A 328 ALA A 338	ADE A 488 (-3.2A) None ADE A 488 (-4.3A) None ADE A 488 (-4.4A) None	1.08A	3cs9A-2qluA: 24.7	3cs9A-2qluA: 24.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 215 LEU A 244 THR A 265 GLY A 271 HIS A 319 LEU A 328 ALA A 338	ADE A 488 (-3.2A) None ADE A 488 (-4.3A) ADE A 488 ( 4.1A) None ADE A 488 (-4.4A) None	0.56A	3cs9A-2qluA: 24.7	3cs9A-2qluA: 24.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 749 LEU A 780 THR A 796 GLY A 802 HIS A 841 LEU A 850	GW7 A 1 (-3.3A) None GW7 A 1 (-4.0A) GW7 A 1 (-3.6A) None GW7 A 1 (-4.2A)	0.75A	3cs9A-2r4bA: 29.6	3cs9A-2r4bA: 36.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xik	SERINE/THREONINE PROTEIN KINASE 25 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 47 GLU A 66 VAL A 69 GLY A 101 LEU A 147 ALA A 157	J60 A1294 (-3.3A) None None J60 A1294 ( 3.8A) J60 A1294 (-4.8A) J60 A1294 ( 4.2A)	0.79A	3cs9A-2xikA: 18.8	3cs9A-2xikA: 27.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	5	ALA A 651 MET A 674 THR A 699 GLY A 705 HIS A 744	Q9G A1898 (-3.2A) Q9G A1898 (-3.9A) Q9G A1898 (-3.5A) Q9G A1898 ( 3.8A) None	0.45A	3cs9A-2xyuA: 27.5	3cs9A-2xyuA: 38.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	ALA A 273 LEU A 302 THR A 319 GLY A 325 HIS A 365 LEU A 374 ALA A 384	None	0.60A	3cs9A-2zv7A: 25.9	3cs9A-2zv7A: 47.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	6	ALA A 273 MET A 294 LEU A 302 THR A 319 HIS A 365 ALA A 384	None	0.78A	3cs9A-2zv7A: 25.9	3cs9A-2zv7A: 47.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 515 MET A 538 ILE A 541 GLY A 570 HIS A 624 LEU A 633 ALA A 643	M33 A1996 (-3.3A) None None M33 A1996 ( 4.8A) None M33 A1996 (-4.5A) None	0.56A	3cs9A-3b2tA: 25.7	3cs9A-3b2tA: 40.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 512 GLU A 531 GLY A 567 HIS A 621 LEU A 630 ALA A 640	C4F A 1 (-3.3A) None None None C4F A 1 (-4.6A) C4F A 1 (-3.6A)	0.61A	3cs9A-3c4fA: 31.8	3cs9A-3c4fA: 40.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 512 GLU A 531 ILE A 538 HIS A 621 LEU A 630 ALA A 640	C4F A 1 (-3.3A) None None None C4F A 1 (-4.6A) C4F A 1 (-3.6A)	0.79A	3cs9A-3c4fA: 31.8	3cs9A-3c4fA: 40.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 512 MET A 535 GLY A 567 HIS A 621 LEU A 630 ALA A 640	C4F A 1 (-3.3A) C4F A 1 ( 3.7A) None None C4F A 1 (-4.6A) C4F A 1 (-3.6A)	0.63A	3cs9A-3c4fA: 31.8	3cs9A-3c4fA: 40.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 512 MET A 535 ILE A 538 HIS A 621 LEU A 630 ALA A 640	C4F A 1 (-3.3A) C4F A 1 ( 3.7A) None None C4F A 1 (-4.6A) C4F A 1 (-3.6A)	0.82A	3cs9A-3c4fA: 31.8	3cs9A-3c4fA: 40.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 220 GLU A 236 MET A 240 LEU A 248 THR A 266 GLY A 272 HIS A 312 LEU A 321	None	0.60A	3cs9A-3d7uA: 27.0	3cs9A-3d7uA: 44.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 220 GLU A 236 VAL A 239 MET A 240 THR A 266 GLY A 272 HIS A 312 LEU A 321	None	0.62A	3cs9A-3d7uA: 27.0	3cs9A-3d7uA: 44.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	ALA A 80 MET A 104 GLY A 135 HIS A 173 LEU A 182 ALA A 192	None	0.75A	3cs9A-3iecA: 22.4	3cs9A-3iecA: 25.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	ALA A 665 GLU A 684 MET A 688 THR A 713 GLY A 719 HIS A 758 LEU A 767	None None None None GOL A 403 (-3.4A) None None	0.60A	3cs9A-3kulA: 32.1	3cs9A-3kulA: 35.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	6	ALA A 229 THR A 279 GLY A 285 HIS A 330 LEU A 339 ALA A 349	LDN A 1 (-3.6A) LDN A 1 (-3.8A) LDN A 1 (-3.3A) None LDN A 1 (-4.5A) LDN A 1 ( 3.8A)	0.46A	3cs9A-3mdyA: 25.2	3cs9A-3mdyA: 28.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 227 THR A 277 GLY A 283 HIS A 328 LEU A 337 ALA A 347	LDN A 600 (-3.2A) LDN A 600 (-4.0A) LDN A 600 (-3.3A) None LDN A 600 (-4.6A) LDN A 600 ( 3.8A)	0.40A	3cs9A-3my0A: 25.0	3cs9A-3my0A: 28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 109 GLU A 130 MET A 134 GLY A 165 HIS A 203 LEU A 212	JOZ A 361 (-3.4A) SO4 A 5 (-3.1A) None None None None	0.62A	3cs9A-3nuuA: 22.7	3cs9A-3nuuA: 25.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 109 GLU A 130 VAL A 133 MET A 134 GLY A 165 LEU A 212	JOZ A 361 (-3.4A) SO4 A 5 (-3.1A) None None None None	0.77A	3cs9A-3nuuA: 22.7	3cs9A-3nuuA: 25.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 751 VAL A 773 THR A 798 GLY A 804 HIS A 843 LEU A 852	03Q A 1 (-3.1A) None 03Q A 1 (-4.1A) 03Q A 1 ( 3.9A) None 03Q A 1 (-4.4A)	1.25A	3cs9A-3pp0A: 29.7	3cs9A-3pp0A: 37.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	6	ALA A 576 MET A 600 THR A 625 GLY A 631 HIS A 674 LEU A 683	STU A 1 (-3.3A) None STU A 1 (-4.1A) STU A 1 (-3.2A) None STU A 1 (-4.3A)	0.41A	3cs9A-3ppzA: 28.7	3cs9A-3ppzA: 35.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	6	GLU A 596 MET A 600 THR A 625 GLY A 631 HIS A 674 LEU A 683	None None STU A 1 (-4.1A) STU A 1 (-3.2A) None STU A 1 (-4.3A)	0.52A	3cs9A-3ppzA: 28.7	3cs9A-3ppzA: 35.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 217 THR A 267 GLY A 273 HIS A 320 LEU A 329 ALA A 339	TAK A 2 (-3.5A) TAK A 2 (-3.5A) TAK A 2 (-3.6A) None TAK A 2 (-4.6A) TAK A 2 ( 4.2A)	0.44A	3cs9A-3q4tA: 24.1	3cs9A-3q4tA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 217 VAL A 235 THR A 267 GLY A 273 LEU A 329 ALA A 339	TAK A 2 (-3.5A) EDO A 489 ( 4.8A) TAK A 2 (-3.5A) TAK A 2 (-3.6A) TAK A 2 (-4.6A) TAK A 2 ( 4.2A)	0.62A	3cs9A-3q4tA: 24.1	3cs9A-3q4tA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 443 MET A 464 LEU A 472 THR A 489 GLY A 495 HIS A 534 LEU A 543	PP2 A 1 (-3.2A) PP2 A 1 ( 4.3A) None PP2 A 1 (-3.3A) PP2 A 1 ( 4.2A) None PP2 A 1 (-4.6A)	0.44A	3cs9A-3sxsA: 25.9	3cs9A-3sxsA: 41.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 512 GLU A 531 MET A 535 GLY A 567 HIS A 621 LEU A 630 ALA A 640	07J A 1 (-3.5A) 07J A 1 (-3.8A) 07J A 1 (-3.8A) 07J A 1 (-3.7A) None 07J A 1 ( 4.4A) 07J A 1 (-3.2A)	0.66A	3cs9A-3tt0A: 30.9	3cs9A-3tt0A: 35.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 512 GLU A 531 MET A 535 ILE A 538 HIS A 621 LEU A 630	07J A 1 (-3.5A) 07J A 1 (-3.8A) 07J A 1 (-3.8A) None None 07J A 1 ( 4.4A)	0.80A	3cs9A-3tt0A: 30.9	3cs9A-3tt0A: 35.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 866 GLU A 885 ILE A 892 GLY A 922 HIS A1026 LEU A1035	4TT A2001 (-3.5A) None None 4TT A2001 (-3.7A) None 4TT A2001 (-4.8A)	0.77A	3cs9A-3vidA: 30.8	3cs9A-3vidA: 34.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 866 GLU A 885 ILE A 892 GLY A 922 HIS A1026 LEU A1035	LEV A1201 (-3.5A) LEV A1201 (-3.7A) None LEV A1201 (-3.6A) None LEV A1201 (-4.8A)	0.70A	3cs9A-3wzdA: 25.8	3cs9A-3wzdA: 38.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 649 THR A 697 GLY A 703 HIS A 742 LEU A 751	None	0.44A	3cs9A-3zfxA: 32.1	3cs9A-3zfxA: 41.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 866 GLU A 885 ILE A 892 GLY A 922 HIS A1026 LEU A1035	B49 A2000 (-3.5A) None None B49 A2000 ( 3.7A) None B49 A2000 (-4.5A)	0.75A	3cs9A-4agdA: 33.2	3cs9A-4agdA: 35.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 586 GLY A 639 PHE A 688 HIS A 690 LEU A 699	LTI A1839 (-3.3A) LTI A1839 (-3.4A) None None LTI A1839 (-4.2A)	0.37A	3cs9A-4at3A: 34.2	3cs9A-4at3A: 37.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	ALA A 233 THR A 283 GLY A 289 HIS A 334 LEU A 343 ALA A 353	TAK A1507 (-3.3A) TAK A1507 (-3.6A) TAK A1507 (-3.5A) None TAK A1507 (-4.7A) TAK A1507 ( 4.2A)	0.32A	3cs9A-4c02A: 25.0	3cs9A-4c02A: 28.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 653 GLU A 672 MET A 676 THR A 701 GLY A 707 HIS A 764 LEU A 773 ALA A 783	DI1 A1000 (-3.6A) DI1 A1000 (-3.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.6A) None DI1 A1000 (-3.8A) DI1 A1000 (-4.5A) DI1 A1000 (-3.7A)	0.72A	3cs9A-4ckrA: 32.8	3cs9A-4ckrA: 37.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	ALA A 684 GLU A 705 LEU A 720 GLY A 743 LEU A 789 ALA A 799	AGS A1985 (-3.5A) None None None AGS A1985 (-4.8A) AGS A1985 ( 4.5A)	0.76A	3cs9A-4crsA: 16.3	3cs9A-4crsA: 26.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A1148 GLU A1167 GLY A1202 PHE A1245 HIS A1247 LEU A1256	0UV A1501 (-3.4A) None 0UV A1501 (-3.6A) None None 0UV A1501 (-4.6A)	0.70A	3cs9A-4fodA: 30.3	3cs9A-4fodA: 36.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 853 GLU A 871 GLY A 908 HIS A 947 LEU A 956 ALA A 966	19S A1201 (-3.3A) None 19S A1201 ( 3.8A) None 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.54A	3cs9A-4hviA: 30.4	3cs9A-4hviA: 35.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	6	ALA A 156 LEU A 189 GLY A 211 PHE A 248 HIS A 250 LEU A 259	None	0.61A	3cs9A-4hzsA: 27.5	3cs9A-4hzsA: 35.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 156 LEU A 189 THR A 205 GLY A 211 HIS A 250 LEU A 259	1G0 A 401 (-3.6A) None 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.5A) None 1G0 A 401 (-4.6A)	0.74A	3cs9A-4id7A: 24.5	3cs9A-4id7A: 39.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLU A 177 LEU A 189 THR A 205 GLY A 211 HIS A 250 LEU A 259	1G0 A 401 ( 4.5A) None 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.5A) None 1G0 A 401 (-4.6A)	0.73A	3cs9A-4id7A: 24.5	3cs9A-4id7A: 39.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 293 LEU A 322 GLY A 344 HIS A 384 LEU A 393 ALA A 403	0J9 A 601 (-3.3A) None 0J9 A 601 ( 4.1A) None 0J9 A 601 (-4.5A) 0J9 A 601 (-3.5A)	0.37A	3cs9A-4k11A: 30.5	3cs9A-4k11A: 33.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 506 GLU A 525 MET A 529 ILE A 532 GLY A 561 LEU A 624 ALA A 634	ACP A 801 (-3.3A) ACP A 801 ( 4.8A) None None ACP A 801 ( 4.6A) ACP A 801 (-4.4A) None	0.78A	3cs9A-4k33A: 26.4	3cs9A-4k33A: 38.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 506 MET A 529 ILE A 532 GLY A 561 HIS A 615 LEU A 624 ALA A 634	ACP A 801 (-3.3A) None None ACP A 801 ( 4.6A) None ACP A 801 (-4.4A) None	0.58A	3cs9A-4k33A: 26.4	3cs9A-4k33A: 38.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ALA A 293 LEU A 322 GLY A 344 HIS A 384 LEU A 393 ALA A 403	VGG A 601 (-3.5A) None VGG A 601 ( 3.2A) None VGG A 601 (-4.5A) VGG A 601 ( 4.2A)	0.49A	3cs9A-4lggA: 30.0	3cs9A-4lggA: 46.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o27	SERINE/THREONINE-PRO TEIN KINASE 24 (Homo sapiens)	PF00069 (Pkinase)	6	ALA B 51 GLU B 70 GLY B 105 HIS B 142 LEU B 151 ALA B 161	ADP B 500 (-3.3A) None None None ADP B 500 (-4.7A) None	0.85A	3cs9A-4o27B: 18.1	3cs9A-4o27B: 29.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o27	SERINE/THREONINE-PRO TEIN KINASE 24 (Homo sapiens)	PF00069 (Pkinase)	6	ALA B 51 GLU B 70 VAL B 73 GLY B 105 LEU B 151 ALA B 161	ADP B 500 (-3.3A) None None None ADP B 500 (-4.7A) None	0.84A	3cs9A-4o27B: 18.1	3cs9A-4o27B: 29.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 67 GLU A 85 MET A 89 THR A 123 GLY A 128 HIS A 171 LEU A 180	SIN A 401 ( 3.7A) None None None SIN A 401 (-3.5A) None SIN A 401 ( 4.5A)	0.83A	3cs9A-4o38A: 19.5	3cs9A-4o38A: 25.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 642 GLU A 661 GLY A 697 HIS A 809 LEU A 818	P30 A1001 (-3.4A) P30 A1001 (-3.6A) P30 A1001 (-3.4A) P30 A1001 ( 4.3A) P30 A1001 (-4.6A)	0.34A	3cs9A-4rt7A: 29.4	3cs9A-4rt7A: 32.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	ALA A 35 ILE A 55 THR A 81 GLY A 87 HIS A 127 LEU A 136 ALA A 146	ACP A1264 (-2.9A) None ACP A1264 (-4.5A) ACP A1264 (-3.5A) None ACP A1264 ( 4.8A) None	1.45A	3cs9A-4ueuA: 32.8	3cs9A-4ueuA: 65.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	ALA A 35 LEU A 64 THR A 81 GLY A 87 HIS A 127 LEU A 136 ALA A 146	ACP A1264 (-2.9A) None ACP A1264 (-4.5A) ACP A1264 (-3.5A) None ACP A1264 ( 4.8A) None	0.45A	3cs9A-4ueuA: 32.8	3cs9A-4ueuA: 65.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	ALA A 35 MET A 56 LEU A 64 THR A 81 HIS A 127 LEU A 136	ACP A1264 (-2.9A) None None ACP A1264 (-4.5A) None ACP A1264 ( 4.8A)	0.81A	3cs9A-4ueuA: 32.8	3cs9A-4ueuA: 65.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 501 GLU A 520 VAL A 523 MET A 524 GLY A 556 HIS A 610 LEU A 619 ALA A 629	40M A1002 ( 4.1A) 40M A1002 (-3.7A) None 40M A1002 (-3.8A) 40M A1002 ( 3.7A) None 40M A1002 (-4.5A) 40M A1002 (-3.0A)	0.62A	3cs9A-4xcuA: 31.6	3cs9A-4xcuA: 39.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 501 GLU A 520 VAL A 523 MET A 524 ILE A 527 HIS A 610	40M A1002 ( 4.1A) 40M A1002 (-3.7A) None 40M A1002 (-3.8A) None None	0.57A	3cs9A-4xcuA: 31.6	3cs9A-4xcuA: 39.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	9	ALA B 288 VAL B 308 MET B 309 LEU B 317 THR B 334 GLY B 340 HIS B 380 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.52A	3cs9A-4xeyB: 35.8	3cs9A-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	8	VAL B 308 MET B 309 ILE B 312 LEU B 317 GLY B 340 HIS B 380 LEU B 389 ALA B 399	None 1N1 B 601 (-3.7A) None None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.66A	3cs9A-4xeyB: 35.8	3cs9A-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 428 LEU A 457 THR A 474 GLY A 480 HIS A 519 LEU A 528	None	0.89A	3cs9A-4xi2A: 25.1	3cs9A-4xi2A: 31.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 428 LEU A 457 THR A 474 GLY A 480 PHE A 517 LEU A 528	None	0.91A	3cs9A-4xi2A: 25.1	3cs9A-4xi2A: 31.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	ALA A 428 LEU A 457 THR A 474 GLY A 480 HIS A 519 LEU A 528	746 A 702 (-2.4A) None 746 A 702 (-3.7A) 746 A 702 (-3.6A) None 746 A 702 (-4.4A)	0.59A	3cs9A-4y93A: 31.5	3cs9A-4y93A: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	ALA A 428 LEU A 457 THR A 474 GLY A 480 PHE A 517 LEU A 528	746 A 702 (-2.4A) None 746 A 702 (-3.7A) 746 A 702 (-3.6A) None 746 A 702 (-4.4A)	0.61A	3cs9A-4y93A: 31.5	3cs9A-4y93A: 28.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 512 GLU A 531 MET A 535 GLY A 567 HIS A 621 LEU A 630 ALA A 640	38O A1769 (-3.6A) EDO A1766 (-4.1A) EDO A1766 (-3.5A) 38O A1769 (-3.4A) None 38O A1769 (-4.6A) EDO A1766 ( 4.4A)	0.62A	3cs9A-5a46A: 30.9	3cs9A-5a46A: 38.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 275 ILE A 293 THR A 325 GLY A 331 HIS A 377 LEU A 386	STU A 601 (-3.1A) None STU A 601 ( 3.7A) STU A 601 (-3.5A) None STU A 601 (-3.9A)	1.19A	3cs9A-5e8yA: 18.6	3cs9A-5e8yA: 27.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 625 GLU A 644 MET A 648 THR A 674 GLY A 680 HIS A 816 LEU A 825	748 A1001 (-3.7A) 748 A1001 (-3.3A) 748 A1001 (-3.4A) 748 A1001 (-3.2A) 748 A1001 ( 4.0A) 748 A1001 (-3.8A) 748 A1001 (-4.3A)	0.51A	3cs9A-5grnA: 29.6	3cs9A-5grnA: 36.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hor	HEPATOCYTE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A1108 GLY A1163 PHE A1200 HIS A1202 ALA A1221	63K A1401 (-3.5A) 63K A1401 (-3.6A) None None 63K A1401 (-3.3A)	0.44A	3cs9A-5horA: 26.7	3cs9A-5horA: 38.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 43 GLU A 61 MET A 65 GLY A 96 HIS A 134 ALA A 153	6G2 A 901 (-3.2A) None None 6G2 A 901 (-3.6A) None 6G2 A 901 ( 4.2A)	0.73A	3cs9A-5j5tA: 21.3	3cs9A-5j5tA: 24.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 43 GLU A 61 MET A 65 GLY A 96 LEU A 143 ALA A 153	6G2 A 901 (-3.2A) None None 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A)	0.69A	3cs9A-5j5tA: 21.3	3cs9A-5j5tA: 24.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 297 GLU A 315 VAL A 318 MET A 319 GLY A 350 HIS A 387 LEU A 396	IPW A 601 (-3.5A) IPW A 601 (-3.9A) None IPW A 601 (-4.1A) IPW A 601 ( 3.8A) None IPW A 601 (-4.5A)	0.83A	3cs9A-5kbrA: 21.8	3cs9A-5kbrA: 24.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 617 MET A 641 GLY A 677 PHE A 719 HIS A 721 ALA A 740	7AE A1000 (-3.3A) None 7AE A1000 ( 3.7A) None None 7AE A1000 ( 3.7A)	0.75A	3cs9A-5td2A: 29.5	3cs9A-5td2A: 42.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 565 GLY A 626 PHE A 668 HIS A 670 ALA A 689	7YS A9001 (-3.3A) 7YS A9001 (-3.4A) None None 7YS A9001 (-3.4A)	0.32A	3cs9A-5u6bA: 30.4	3cs9A-5u6bA: 43.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	6	ALA A 917 LEU A 946 THR A 963 GLY A 969 HIS A1008 LEU A1017	ANP A1201 (-3.3A) None ANP A1201 (-3.9A) ANP A1201 ( 4.6A) None ANP A1201 (-4.7A)	0.53A	3cs9A-5wnoA: 28.1	3cs9A-5wnoA: 17.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	5	ALA A 155 GLY A 236 HIS A 273 LEU A 282 ALA A 292	H1N A 501 (-3.4A) H1N A 501 (-3.6A) None H1N A 501 (-4.8A) H1N A 501 ( 3.9A)	0.37A	3cs9A-6ccfA: 22.2	3cs9A-6ccfA: 14.13

[["3CS9_A_NILA600_2","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"ALA A 428;LEU A 457;THR A 474;GLY A 480;PHE A 517;HIS A 519;LEU A 528","None","0.66A","3cs9A-1k2pA:25.6","3cs9A-1k2pA:45.68"],["3CS9_A_NILA600_2","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"ALA A 220;GLU A 236;MET A 240;LEU A 248;THR A 266;GLY A 272;HIS A 312;LEU A 321","None","0.60A","3cs9A-1k9aA:31.2","3cs9A-1k9aA:31.07"],["3CS9_A_NILA600_2","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"ALA A 220;GLU A 236;VAL A 239;MET A 240;THR A 266;GLY A 272;HIS A 312;LEU A 321","None","0.62A","3cs9A-1k9aA:31.2","3cs9A-1k9aA:31.07"],["3CS9_A_NILA600_2","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",6,"ALA A 606;GLY A 660;PHE A 720;HIS A 722;LEU A 731;ALA A 741","None","0.60A","3cs9A-1lufA:35.4","3cs9A-1lufA:37.76"],["3CS9_A_NILA600_2","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",10,"ALA A 288;GLU A 305;VAL A 308;MET A 309;LEU A 317;THR A 334;GLY A 340;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.59A","3cs9A-1opkA:34.8","3cs9A-1opkA:57.29"],["3CS9_A_NILA600_2","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",10,"GLU A 305;VAL A 308;MET A 309;ILE A 312;LEU A 317;THR A 334;GLY A 340;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-4.2A);None;P16 A   2 (-3.3A);None;None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.70A","3cs9A-1opkA:34.8","3cs9A-1opkA:57.29"],["3CS9_A_NILA600_2","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",5,"ALA A 230;GLY A 286;HIS A 331;LEU A 340;ALA A 350","PY1 A 700 (-3.5A);PY1 A 700 (-3.6A);None;PY1 A 700 (-4.4A);PY1 A 700 ( 4.2A)","0.39A","3cs9A-1py5A:26.0","3cs9A-1py5A:27.94"],["3CS9_A_NILA600_2","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",5,"ALA A 389;LEU A 418;GLY A 441;HIS A 480;LEU A 489","None","0.41A","3cs9A-1snxA:22.5","3cs9A-1snxA:41.73"],["3CS9_A_NILA600_2","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",7,"ALA A 621;GLU A 640;VAL A 643;THR A 670;GLY A 676;HIS A 790;LEU A 799","STI A   3 (-3.5A);STI A   3 (-3.6A);None;STI A   3 (-3.2A);STI A   3 ( 3.8A);STI A   3 (-4.5A);STI A   3 (-4.4A)","0.50A","3cs9A-1t46A:34.7","3cs9A-1t46A:37.06"],["3CS9_A_NILA600_2","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",6,"ALA A 367;GLU A 386;MET A 390;GLY A 420;HIS A 459;LEU A 468","STU A 100 (-3.2A);None;None;STU A 100 (-3.5A);None;STU A 100 (-4.5A)","0.64A","3cs9A-1u59A:30.7","3cs9A-1u59A:38.19"],["3CS9_A_NILA600_2","2buj","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 16","PF00069(Pkinase)",5,"ALA A  47;GLU A  65;GLY A 104;HIS A 146;LEU A 155","STU A1301 (-3.6A);None;STU A1301 ( 4.0A);None;STU A1301 ( 4.8A)","0.43A","3cs9A-2bujA:23.0","3cs9A-2bujA:23.88"],["3CS9_A_NILA600_2","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",8,"ALA X  37;GLU X  54;MET X  58;LEU X  66;THR X  82;GLY X  88;LEU X 137;ALA X 147","STU X 902 (-3.1A);STU X 902 ( 4.4A);None;None;STU X 902 (-4.1A);STU X 902 (-3.5A);STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.71A","3cs9A-2dq7X:32.3","3cs9A-2dq7X:45.45"],["3CS9_A_NILA600_2","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",8,"ALA X  37;MET X  58;LEU X  66;THR X  82;GLY X  88;HIS X 128;LEU X 137;ALA X 147","STU X 902 (-3.1A);None;None;STU X 902 (-4.1A);STU X 902 (-3.5A);None;STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.59A","3cs9A-2dq7X:32.3","3cs9A-2dq7X:45.45"],["3CS9_A_NILA600_2","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",6,"ALA A 184;GLU A 201;VAL A 204;GLY A 240;LEU A 290;ALA A 319","None","1.17A","3cs9A-2eu9A:21.4","3cs9A-2eu9A:24.24"],["3CS9_A_NILA600_2","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",6,"ALA A 184;GLU A 201;VAL A 204;ILE A 208;LEU A 290;ALA A 319","None","0.91A","3cs9A-2eu9A:21.4","3cs9A-2eu9A:24.24"],["3CS9_A_NILA600_2","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"ALA A 293;LEU A 322;THR A 338;GLY A 344;HIS A 384;LEU A 393;ALA A 403","H8H A 534 (-3.2A);None;H8H A 534 (-3.1A);H8H A 534 (-3.3A);None;H8H A 534 (-4.5A);H8H A 534 ( 4.0A)","0.59A","3cs9A-2h8hA:30.7","3cs9A-2h8hA:27.93"],["3CS9_A_NILA600_2","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 293;LEU A 322;GLY A 344;HIS A 384;LEU A 393;ALA A 403","QUE A   1 (-3.5A);None;QUE A   1 (-3.0A);None;QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","0.45A","3cs9A-2hckA:30.2","3cs9A-2hckA:30.67"],["3CS9_A_NILA600_2","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 293;LEU A 322;THR A 338;GLY A 344;LEU A 393;ALA A 403","QUE A   1 (-3.5A);None;QUE A   1 (-3.3A);QUE A   1 (-3.0A);QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","0.58A","3cs9A-2hckA:30.2","3cs9A-2hckA:30.67"],["3CS9_A_NILA600_2","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",6,"ALA A 271;GLU A 288;VAL A 291;MET A 292;LEU A 300;THR A 316","1BM A 499 (-3.6A);1BM A 499 (-3.2A);None;1BM A 499 ( 3.8A);None;1BM A 499 (-3.2A)","0.57A","3cs9A-2hk5A:27.5","3cs9A-2hk5A:48.00"],["3CS9_A_NILA600_2","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",9,"ALA A 271;VAL A 291;MET A 292;LEU A 300;THR A 316;GLY A 322;HIS A 362;LEU A 371;ALA A 381","1BM A 499 (-3.6A);None;1BM A 499 ( 3.8A);None;1BM A 499 (-3.2A);1BM A 499 (-3.5A);None;1BM A 499 (-4.4A);1BM A 499 ( 3.7A)","0.64A","3cs9A-2hk5A:27.5","3cs9A-2hk5A:48.00"],["3CS9_A_NILA600_2","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",10,"ALA A 269;GLU A 286;VAL A 289;MET A 290;ILE A 293;LEU A 298;THR A 315;GLY A 321;LEU A 370;ALA A 380","GIN A 600 (-3.1A);GIN A 600 (-3.6A);None;GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.2A);GIN A 600 (-3.4A);None;GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.57A","3cs9A-2hz0A:35.0","3cs9A-2hz0A:98.18"],["3CS9_A_NILA600_2","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",9,"VAL A 289;MET A 290;ILE A 293;LEU A 298;THR A 315;GLY A 321;HIS A 361;LEU A 370;ALA A 380","None;GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.2A);GIN A 600 (-3.4A);None;GIN A 600 (-4.3A);GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.72A","3cs9A-2hz0A:35.0","3cs9A-2hz0A:98.18"],["3CS9_A_NILA600_2","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",7,"ALA A 452;GLU A 471;MET A 475;GLY A 505;PHE A 542;HIS A 544;LEU A 553","4ST A1687 (-3.3A);4ST A1687 ( 4.6A);None;4ST A1687 (-3.2A);None;None;4ST A1687 (-4.4A)","0.69A","3cs9A-2j0jA:32.7","3cs9A-2j0jA:20.00"],["3CS9_A_NILA600_2","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",6,"ALA A 452;MET A 475;GLY A 505;PHE A 542;HIS A 544;LEU A 553","BII A1687 (-3.5A);None;BII A1687 (-3.6A);None;None;BII A1687 (-4.2A)","0.66A","3cs9A-2jkmA:32.5","3cs9A-2jkmA:40.78"],["3CS9_A_NILA600_2","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",9,"ALA A 271;GLU A 288;MET A 292;LEU A 300;THR A 316;GLY A 322;HIS A 362;LEU A 371;ALA A 381","1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.9A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.5A);None;1N8 A 501 ( 4.3A);1N8 A 501 ( 3.3A)","0.46A","3cs9A-2og8A:32.4","3cs9A-2og8A:47.97"],["3CS9_A_NILA600_2","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"ALA A 614;GLU A 633;MET A 637;THR A 663;GLY A 669;HIS A 776;LEU A 785","None","0.72A","3cs9A-2ogvA:32.7","3cs9A-2ogvA:38.89"],["3CS9_A_NILA600_2","2p4i","Homo sapiens","ANGIOPOIETIN-1 RECEPTOR","PF07714(Pkinase_Tyr)",6,"ALA A 853;VAL A 875;GLY A 908;HIS A 962;LEU A 971;ALA A 981","MR9 A 301 (-3.5A);MR9 A 301 ( 4.8A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A)","0.40A","3cs9A-2p4iA:23.9","3cs9A-2p4iA:37.30"],["3CS9_A_NILA600_2","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"ALA A 515;GLU A 534;MET A 538;ILE A 541;GLY A 570;LEU A 633;ALA A 643","None","0.71A","3cs9A-2psqA:32.5","3cs9A-2psqA:35.50"],["3CS9_A_NILA600_2","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"ALA A 515;MET A 538;ILE A 541;GLY A 570;HIS A 624;LEU A 633;ALA A 643","None","0.58A","3cs9A-2psqA:32.5","3cs9A-2psqA:35.50"],["3CS9_A_NILA600_2","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"ALA A 215;ILE A 233;THR A 265;HIS A 319;LEU A 328;ALA A 338","ADE A 488 (-3.2A);None;ADE A 488 (-4.3A);None;ADE A 488 (-4.4A);None","1.08A","3cs9A-2qluA:24.7","3cs9A-2qluA:24.69"],["3CS9_A_NILA600_2","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",7,"ALA A 215;LEU A 244;THR A 265;GLY A 271;HIS A 319;LEU A 328;ALA A 338","ADE A 488 (-3.2A);None;ADE A 488 (-4.3A);ADE A 488 ( 4.1A);None;ADE A 488 (-4.4A);None","0.56A","3cs9A-2qluA:24.7","3cs9A-2qluA:24.69"],["3CS9_A_NILA600_2","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"ALA A 749;LEU A 780;THR A 796;GLY A 802;HIS A 841;LEU A 850","GW7 A   1 (-3.3A);None;GW7 A   1 (-4.0A);GW7 A   1 (-3.6A);None;GW7 A   1 (-4.2A)","0.75A","3cs9A-2r4bA:29.6","3cs9A-2r4bA:36.79"],["3CS9_A_NILA600_2","2xik","Homo sapiens","SERINE\/THREONINE PROTEIN KINASE 25","PF00069(Pkinase)",6,"ALA A  47;GLU A  66;VAL A  69;GLY A 101;LEU A 147;ALA A 157","J60 A1294 (-3.3A);None;None;J60 A1294 ( 3.8A);J60 A1294 (-4.8A);J60 A1294 ( 4.2A)","0.79A","3cs9A-2xikA:18.8","3cs9A-2xikA:27.67"],["3CS9_A_NILA600_2","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",5,"ALA A 651;MET A 674;THR A 699;GLY A 705;HIS A 744","Q9G A1898 (-3.2A);Q9G A1898 (-3.9A);Q9G A1898 (-3.5A);Q9G A1898 ( 3.8A);None","0.45A","3cs9A-2xyuA:27.5","3cs9A-2xyuA:38.31"],["3CS9_A_NILA600_2","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"ALA A 273;LEU A 302;THR A 319;GLY A 325;HIS A 365;LEU A 374;ALA A 384","None","0.60A","3cs9A-2zv7A:25.9","3cs9A-2zv7A:47.18"],["3CS9_A_NILA600_2","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",6,"ALA A 273;MET A 294;LEU A 302;THR A 319;HIS A 365;ALA A 384","None","0.78A","3cs9A-2zv7A:25.9","3cs9A-2zv7A:47.18"],["3CS9_A_NILA600_2","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"ALA A 515;MET A 538;ILE A 541;GLY A 570;HIS A 624;LEU A 633;ALA A 643","M33 A1996 (-3.3A);None;None;M33 A1996 ( 4.8A);None;M33 A1996 (-4.5A);None","0.56A","3cs9A-3b2tA:25.7","3cs9A-3b2tA:40.45"],["3CS9_A_NILA600_2","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ALA A 512;GLU A 531;GLY A 567;HIS A 621;LEU A 630;ALA A 640","C4F A   1 (-3.3A);None;None;None;C4F A   1 (-4.6A);C4F A   1 (-3.6A)","0.61A","3cs9A-3c4fA:31.8","3cs9A-3c4fA:40.45"],["3CS9_A_NILA600_2","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ALA A 512;GLU A 531;ILE A 538;HIS A 621;LEU A 630;ALA A 640","C4F A   1 (-3.3A);None;None;None;C4F A   1 (-4.6A);C4F A   1 (-3.6A)","0.79A","3cs9A-3c4fA:31.8","3cs9A-3c4fA:40.45"],["3CS9_A_NILA600_2","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ALA A 512;MET A 535;GLY A 567;HIS A 621;LEU A 630;ALA A 640","C4F A   1 (-3.3A);C4F A   1 ( 3.7A);None;None;C4F A   1 (-4.6A);C4F A   1 (-3.6A)","0.63A","3cs9A-3c4fA:31.8","3cs9A-3c4fA:40.45"],["3CS9_A_NILA600_2","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ALA A 512;MET A 535;ILE A 538;HIS A 621;LEU A 630;ALA A 640","C4F A   1 (-3.3A);C4F A   1 ( 3.7A);None;None;C4F A   1 (-4.6A);C4F A   1 (-3.6A)","0.82A","3cs9A-3c4fA:31.8","3cs9A-3c4fA:40.45"],["3CS9_A_NILA600_2","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",8,"ALA A 220;GLU A 236;MET A 240;LEU A 248;THR A 266;GLY A 272;HIS A 312;LEU A 321","None","0.60A","3cs9A-3d7uA:27.0","3cs9A-3d7uA:44.10"],["3CS9_A_NILA600_2","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",8,"ALA A 220;GLU A 236;VAL A 239;MET A 240;THR A 266;GLY A 272;HIS A 312;LEU A 321","None","0.62A","3cs9A-3d7uA:27.0","3cs9A-3d7uA:44.10"],["3CS9_A_NILA600_2","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",6,"ALA A  80;MET A 104;GLY A 135;HIS A 173;LEU A 182;ALA A 192","None","0.75A","3cs9A-3iecA:22.4","3cs9A-3iecA:25.93"],["3CS9_A_NILA600_2","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"ALA A 665;GLU A 684;MET A 688;THR A 713;GLY A 719;HIS A 758;LEU A 767","None;None;None;None;GOL A 403 (-3.4A);None;None","0.60A","3cs9A-3kulA:32.1","3cs9A-3kulA:35.31"],["3CS9_A_NILA600_2","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",6,"ALA A 229;THR A 279;GLY A 285;HIS A 330;LEU A 339;ALA A 349","LDN A   1 (-3.6A);LDN A   1 (-3.8A);LDN A   1 (-3.3A);None;LDN A   1 (-4.5A);LDN A   1 ( 3.8A)","0.46A","3cs9A-3mdyA:25.2","3cs9A-3mdyA:28.36"],["3CS9_A_NILA600_2","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",6,"ALA A 227;THR A 277;GLY A 283;HIS A 328;LEU A 337;ALA A 347","LDN A 600 (-3.2A);LDN A 600 (-4.0A);LDN A 600 (-3.3A);None;LDN A 600 (-4.6A);LDN A 600 ( 3.8A)","0.40A","3cs9A-3my0A:25.0","3cs9A-3my0A:28.12"],["3CS9_A_NILA600_2","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"ALA A 109;GLU A 130;MET A 134;GLY A 165;HIS A 203;LEU A 212","JOZ A 361 (-3.4A);SO4 A   5 (-3.1A);None;None;None;None","0.62A","3cs9A-3nuuA:22.7","3cs9A-3nuuA:25.93"],["3CS9_A_NILA600_2","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"ALA A 109;GLU A 130;VAL A 133;MET A 134;GLY A 165;LEU A 212","JOZ A 361 (-3.4A);SO4 A   5 (-3.1A);None;None;None;None","0.77A","3cs9A-3nuuA:22.7","3cs9A-3nuuA:25.93"],["3CS9_A_NILA600_2","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"ALA A 751;VAL A 773;THR A 798;GLY A 804;HIS A 843;LEU A 852","03Q A   1 (-3.1A);None;03Q A   1 (-4.1A);03Q A   1 ( 3.9A);None;03Q A   1 (-4.4A)","1.25A","3cs9A-3pp0A:29.7","3cs9A-3pp0A:37.22"],["3CS9_A_NILA600_2","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",6,"ALA A 576;MET A 600;THR A 625;GLY A 631;HIS A 674;LEU A 683","STU A   1 (-3.3A);None;STU A   1 (-4.1A);STU A   1 (-3.2A);None;STU A   1 (-4.3A)","0.41A","3cs9A-3ppzA:28.7","3cs9A-3ppzA:35.86"],["3CS9_A_NILA600_2","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",6,"GLU A 596;MET A 600;THR A 625;GLY A 631;HIS A 674;LEU A 683","None;None;STU A   1 (-4.1A);STU A   1 (-3.2A);None;STU A   1 (-4.3A)","0.52A","3cs9A-3ppzA:28.7","3cs9A-3ppzA:35.86"],["3CS9_A_NILA600_2","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",6,"ALA A 217;THR A 267;GLY A 273;HIS A 320;LEU A 329;ALA A 339","TAK A   2 (-3.5A);TAK A   2 (-3.5A);TAK A   2 (-3.6A);None;TAK A   2 (-4.6A);TAK A   2 ( 4.2A)","0.44A","3cs9A-3q4tA:24.1","3cs9A-3q4tA:25.00"],["3CS9_A_NILA600_2","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",6,"ALA A 217;VAL A 235;THR A 267;GLY A 273;LEU A 329;ALA A 339","TAK A   2 (-3.5A);EDO A 489 ( 4.8A);TAK A   2 (-3.5A);TAK A   2 (-3.6A);TAK A   2 (-4.6A);TAK A   2 ( 4.2A)","0.62A","3cs9A-3q4tA:24.1","3cs9A-3q4tA:25.00"],["3CS9_A_NILA600_2","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",7,"ALA A 443;MET A 464;LEU A 472;THR A 489;GLY A 495;HIS A 534;LEU A 543","PP2 A   1 (-3.2A);PP2 A   1 ( 4.3A);None;PP2 A   1 (-3.3A);PP2 A   1 ( 4.2A);None;PP2 A   1 (-4.6A)","0.44A","3cs9A-3sxsA:25.9","3cs9A-3sxsA:41.16"],["3CS9_A_NILA600_2","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"ALA A 512;GLU A 531;MET A 535;GLY A 567;HIS A 621;LEU A 630;ALA A 640","07J A   1 (-3.5A);07J A   1 (-3.8A);07J A   1 (-3.8A);07J A   1 (-3.7A);None;07J A   1 ( 4.4A);07J A   1 (-3.2A)","0.66A","3cs9A-3tt0A:30.9","3cs9A-3tt0A:35.73"],["3CS9_A_NILA600_2","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ALA A 512;GLU A 531;MET A 535;ILE A 538;HIS A 621;LEU A 630","07J A   1 (-3.5A);07J A   1 (-3.8A);07J A   1 (-3.8A);None;None;07J A   1 ( 4.4A)","0.80A","3cs9A-3tt0A:30.9","3cs9A-3tt0A:35.73"],["3CS9_A_NILA600_2","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"ALA A 866;GLU A 885;ILE A 892;GLY A 922;HIS A1026;LEU A1035","4TT A2001 (-3.5A);None;None;4TT A2001 (-3.7A);None;4TT A2001 (-4.8A)","0.77A","3cs9A-3vidA:30.8","3cs9A-3vidA:34.44"],["3CS9_A_NILA600_2","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"ALA A 866;GLU A 885;ILE A 892;GLY A 922;HIS A1026;LEU A1035","LEV A1201 (-3.5A);LEV A1201 (-3.7A);None;LEV A1201 (-3.6A);None;LEV A1201 (-4.8A)","0.70A","3cs9A-3wzdA:25.8","3cs9A-3wzdA:38.29"],["3CS9_A_NILA600_2","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"ALA A 649;THR A 697;GLY A 703;HIS A 742;LEU A 751","None","0.44A","3cs9A-3zfxA:32.1","3cs9A-3zfxA:41.38"],["3CS9_A_NILA600_2","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"ALA A 866;GLU A 885;ILE A 892;GLY A 922;HIS A1026;LEU A1035","B49 A2000 (-3.5A);None;None;B49 A2000 ( 3.7A);None;B49 A2000 (-4.5A)","0.75A","3cs9A-4agdA:33.2","3cs9A-4agdA:35.28"],["3CS9_A_NILA600_2","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",5,"ALA A 586;GLY A 639;PHE A 688;HIS A 690;LEU A 699","LTI A1839 (-3.3A);LTI A1839 (-3.4A);None;None;LTI A1839 (-4.2A)","0.37A","3cs9A-4at3A:34.2","3cs9A-4at3A:37.97"],["3CS9_A_NILA600_2","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"ALA A 233;THR A 283;GLY A 289;HIS A 334;LEU A 343;ALA A 353","TAK A1507 (-3.3A);TAK A1507 (-3.6A);TAK A1507 (-3.5A);None;TAK A1507 (-4.7A);TAK A1507 ( 4.2A)","0.32A","3cs9A-4c02A:25.0","3cs9A-4c02A:28.27"],["3CS9_A_NILA600_2","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"ALA A 653;GLU A 672;MET A 676;THR A 701;GLY A 707;HIS A 764;LEU A 773;ALA A 783","DI1 A1000 (-3.6A);DI1 A1000 (-3.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.6A);None;DI1 A1000 (-3.8A);DI1 A1000 (-4.5A);DI1 A1000 (-3.7A)","0.72A","3cs9A-4ckrA:32.8","3cs9A-4ckrA:37.58"],["3CS9_A_NILA600_2","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",6,"ALA A 684;GLU A 705;LEU A 720;GLY A 743;LEU A 789;ALA A 799","AGS A1985 (-3.5A);None;None;None;AGS A1985 (-4.8A);AGS A1985 ( 4.5A)","0.76A","3cs9A-4crsA:16.3","3cs9A-4crsA:26.30"],["3CS9_A_NILA600_2","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",6,"ALA A1148;GLU A1167;GLY A1202;PHE A1245;HIS A1247;LEU A1256","0UV A1501 (-3.4A);None;0UV A1501 (-3.6A);None;None;0UV A1501 (-4.6A)","0.70A","3cs9A-4fodA:30.3","3cs9A-4fodA:36.94"],["3CS9_A_NILA600_2","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",6,"ALA A 853;GLU A 871;GLY A 908;HIS A 947;LEU A 956;ALA A 966","19S A1201 (-3.3A);None;19S A1201 ( 3.8A);None;19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.54A","3cs9A-4hviA:30.4","3cs9A-4hviA:35.19"],["3CS9_A_NILA600_2","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",6,"ALA A 156;LEU A 189;GLY A 211;PHE A 248;HIS A 250;LEU A 259","None","0.61A","3cs9A-4hzsA:27.5","3cs9A-4hzsA:35.59"],["3CS9_A_NILA600_2","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"ALA A 156;LEU A 189;THR A 205;GLY A 211;HIS A 250;LEU A 259","1G0 A 401 (-3.6A);None;1G0 A 401 (-3.2A);1G0 A 401 ( 4.5A);None;1G0 A 401 (-4.6A)","0.74A","3cs9A-4id7A:24.5","3cs9A-4id7A:39.65"],["3CS9_A_NILA600_2","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"GLU A 177;LEU A 189;THR A 205;GLY A 211;HIS A 250;LEU A 259","1G0 A 401 ( 4.5A);None;1G0 A 401 (-3.2A);1G0 A 401 ( 4.5A);None;1G0 A 401 (-4.6A)","0.73A","3cs9A-4id7A:24.5","3cs9A-4id7A:39.65"],["3CS9_A_NILA600_2","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 293;LEU A 322;GLY A 344;HIS A 384;LEU A 393;ALA A 403","0J9 A 601 (-3.3A);None;0J9 A 601 ( 4.1A);None;0J9 A 601 (-4.5A);0J9 A 601 (-3.5A)","0.37A","3cs9A-4k11A:30.5","3cs9A-4k11A:33.03"],["3CS9_A_NILA600_2","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"ALA A 506;GLU A 525;MET A 529;ILE A 532;GLY A 561;LEU A 624;ALA A 634","ACP A 801 (-3.3A);ACP A 801 ( 4.8A);None;None;ACP A 801 ( 4.6A);ACP A 801 (-4.4A);None","0.78A","3cs9A-4k33A:26.4","3cs9A-4k33A:38.23"],["3CS9_A_NILA600_2","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"ALA A 506;MET A 529;ILE A 532;GLY A 561;HIS A 615;LEU A 624;ALA A 634","ACP A 801 (-3.3A);None;None;ACP A 801 ( 4.6A);None;ACP A 801 (-4.4A);None","0.58A","3cs9A-4k33A:26.4","3cs9A-4k33A:38.23"],["3CS9_A_NILA600_2","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",6,"ALA A 293;LEU A 322;GLY A 344;HIS A 384;LEU A 393;ALA A 403","VGG A 601 (-3.5A);None;VGG A 601 ( 3.2A);None;VGG A 601 (-4.5A);VGG A 601 ( 4.2A)","0.49A","3cs9A-4lggA:30.0","3cs9A-4lggA:46.34"],["3CS9_A_NILA600_2","4o27","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 24","PF00069(Pkinase)",6,"ALA B  51;GLU B  70;GLY B 105;HIS B 142;LEU B 151;ALA B 161","ADP B 500 (-3.3A);None;None;None;ADP B 500 (-4.7A);None","0.85A","3cs9A-4o27B:18.1","3cs9A-4o27B:29.31"],["3CS9_A_NILA600_2","4o27","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 24","PF00069(Pkinase)",6,"ALA B  51;GLU B  70;VAL B  73;GLY B 105;LEU B 151;ALA B 161","ADP B 500 (-3.3A);None;None;None;ADP B 500 (-4.7A);None","0.84A","3cs9A-4o27B:18.1","3cs9A-4o27B:29.31"],["3CS9_A_NILA600_2","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",7,"ALA A  67;GLU A  85;MET A  89;THR A 123;GLY A 128;HIS A 171;LEU A 180","SIN A 401 ( 3.7A);None;None;None;SIN A 401 (-3.5A);None;SIN A 401 ( 4.5A)","0.83A","3cs9A-4o38A:19.5","3cs9A-4o38A:25.53"],["3CS9_A_NILA600_2","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",5,"ALA A 642;GLU A 661;GLY A 697;HIS A 809;LEU A 818","P30 A1001 (-3.4A);P30 A1001 (-3.6A);P30 A1001 (-3.4A);P30 A1001 ( 4.3A);P30 A1001 (-4.6A)","0.34A","3cs9A-4rt7A:29.4","3cs9A-4rt7A:32.03"],["3CS9_A_NILA600_2","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"ALA A  35;ILE A  55;THR A  81;GLY A  87;HIS A 127;LEU A 136;ALA A 146","ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);ACP A1264 (-3.5A);None;ACP A1264 ( 4.8A);None","1.45A","3cs9A-4ueuA:32.8","3cs9A-4ueuA:65.83"],["3CS9_A_NILA600_2","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"ALA A  35;LEU A  64;THR A  81;GLY A  87;HIS A 127;LEU A 136;ALA A 146","ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);ACP A1264 (-3.5A);None;ACP A1264 ( 4.8A);None","0.45A","3cs9A-4ueuA:32.8","3cs9A-4ueuA:65.83"],["3CS9_A_NILA600_2","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"ALA A  35;MET A  56;LEU A  64;THR A  81;HIS A 127;LEU A 136","ACP A1264 (-2.9A);None;None;ACP A1264 (-4.5A);None;ACP A1264 ( 4.8A)","0.81A","3cs9A-4ueuA:32.8","3cs9A-4ueuA:65.83"],["3CS9_A_NILA600_2","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",8,"ALA A 501;GLU A 520;VAL A 523;MET A 524;GLY A 556;HIS A 610;LEU A 619;ALA A 629","40M A1002 ( 4.1A);40M A1002 (-3.7A);None;40M A1002 (-3.8A);40M A1002 ( 3.7A);None;40M A1002 (-4.5A);40M A1002 (-3.0A)","0.62A","3cs9A-4xcuA:31.6","3cs9A-4xcuA:39.67"],["3CS9_A_NILA600_2","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"ALA A 501;GLU A 520;VAL A 523;MET A 524;ILE A 527;HIS A 610","40M A1002 ( 4.1A);40M A1002 (-3.7A);None;40M A1002 (-3.8A);None;None","0.57A","3cs9A-4xcuA:31.6","3cs9A-4xcuA:39.67"],["3CS9_A_NILA600_2","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",9,"ALA B 288;VAL B 308;MET B 309;LEU B 317;THR B 334;GLY B 340;HIS B 380;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.52A","3cs9A-4xeyB:35.8","3cs9A-4xeyB:74.39"],["3CS9_A_NILA600_2","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",8,"VAL B 308;MET B 309;ILE B 312;LEU B 317;GLY B 340;HIS B 380;LEU B 389;ALA B 399","None;1N1 B 601 (-3.7A);None;None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.66A","3cs9A-4xeyB:35.8","3cs9A-4xeyB:74.39"],["3CS9_A_NILA600_2","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 428;LEU A 457;THR A 474;GLY A 480;HIS A 519;LEU A 528","None","0.89A","3cs9A-4xi2A:25.1","3cs9A-4xi2A:31.60"],["3CS9_A_NILA600_2","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 428;LEU A 457;THR A 474;GLY A 480;PHE A 517;LEU A 528","None","0.91A","3cs9A-4xi2A:25.1","3cs9A-4xi2A:31.60"],["3CS9_A_NILA600_2","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"ALA A 428;LEU A 457;THR A 474;GLY A 480;HIS A 519;LEU A 528","746 A 702 (-2.4A);None;746 A 702 (-3.7A);746 A 702 (-3.6A);None;746 A 702 (-4.4A)","0.59A","3cs9A-4y93A:31.5","3cs9A-4y93A:28.57"],["3CS9_A_NILA600_2","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"ALA A 428;LEU A 457;THR A 474;GLY A 480;PHE A 517;LEU A 528","746 A 702 (-2.4A);None;746 A 702 (-3.7A);746 A 702 (-3.6A);None;746 A 702 (-4.4A)","0.61A","3cs9A-4y93A:31.5","3cs9A-4y93A:28.57"],["3CS9_A_NILA600_2","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",7,"ALA A 512;GLU A 531;MET A 535;GLY A 567;HIS A 621;LEU A 630;ALA A 640","38O A1769 (-3.6A);EDO A1766 (-4.1A);EDO A1766 (-3.5A);38O A1769 (-3.4A);None;38O A1769 (-4.6A);EDO A1766 ( 4.4A)","0.62A","3cs9A-5a46A:30.9","3cs9A-5a46A:38.62"],["3CS9_A_NILA600_2","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",6,"ALA A 275;ILE A 293;THR A 325;GLY A 331;HIS A 377;LEU A 386","STU A 601 (-3.1A);None;STU A 601 ( 3.7A);STU A 601 (-3.5A);None;STU A 601 (-3.9A)","1.19A","3cs9A-5e8yA:18.6","3cs9A-5e8yA:27.86"],["3CS9_A_NILA600_2","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",7,"ALA A 625;GLU A 644;MET A 648;THR A 674;GLY A 680;HIS A 816;LEU A 825","748 A1001 (-3.7A);748 A1001 (-3.3A);748 A1001 (-3.4A);748 A1001 (-3.2A);748 A1001 ( 4.0A);748 A1001 (-3.8A);748 A1001 (-4.3A)","0.51A","3cs9A-5grnA:29.6","3cs9A-5grnA:36.39"],["3CS9_A_NILA600_2","5hor","Homo sapiens","HEPATOCYTE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"ALA A1108;GLY A1163;PHE A1200;HIS A1202;ALA A1221","63K A1401 (-3.5A);63K A1401 (-3.6A);None;None;63K A1401 (-3.3A)","0.44A","3cs9A-5horA:26.7","3cs9A-5horA:38.89"],["3CS9_A_NILA600_2","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"ALA A  43;GLU A  61;MET A  65;GLY A  96;HIS A 134;ALA A 153","6G2 A 901 (-3.2A);None;None;6G2 A 901 (-3.6A);None;6G2 A 901 ( 4.2A)","0.73A","3cs9A-5j5tA:21.3","3cs9A-5j5tA:24.13"],["3CS9_A_NILA600_2","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"ALA A  43;GLU A  61;MET A  65;GLY A  96;LEU A 143;ALA A 153","6G2 A 901 (-3.2A);None;None;6G2 A 901 (-3.6A);6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A)","0.69A","3cs9A-5j5tA:21.3","3cs9A-5j5tA:24.13"],["3CS9_A_NILA600_2","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",7,"ALA A 297;GLU A 315;VAL A 318;MET A 319;GLY A 350;HIS A 387;LEU A 396","IPW A 601 (-3.5A);IPW A 601 (-3.9A);None;IPW A 601 (-4.1A);IPW A 601 ( 3.8A);None;IPW A 601 (-4.5A)","0.83A","3cs9A-5kbrA:21.8","3cs9A-5kbrA:24.30"],["3CS9_A_NILA600_2","5td2","Homo sapiens","TYROSINE-PROTEIN KINASE MER","PF07714(Pkinase_Tyr)",6,"ALA A 617;MET A 641;GLY A 677;PHE A 719;HIS A 721;ALA A 740","7AE A1000 (-3.3A);None;7AE A1000 ( 3.7A);None;None;7AE A1000 ( 3.7A)","0.75A","3cs9A-5td2A:29.5","3cs9A-5td2A:42.66"],["3CS9_A_NILA600_2","5u6b","Homo sapiens","TYROSINE-PROTEIN KINASE RECEPTOR UFO","PF07714(Pkinase_Tyr)",5,"ALA A 565;GLY A 626;PHE A 668;HIS A 670;ALA A 689","7YS A9001 (-3.3A);7YS A9001 (-3.4A);None;None;7YS A9001 (-3.4A)","0.32A","3cs9A-5u6bA:30.4","3cs9A-5u6bA:43.27"],["3CS9_A_NILA600_2","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",6,"ALA A 917;LEU A 946;THR A 963;GLY A 969;HIS A1008;LEU A1017","ANP A1201 (-3.3A);None;ANP A1201 (-3.9A);ANP A1201 ( 4.6A);None;ANP A1201 (-4.7A)","0.53A","3cs9A-5wnoA:28.1","3cs9A-5wnoA:17.34"],["3CS9_A_NILA600_2","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",5,"ALA A 155;GLY A 236;HIS A 273;LEU A 282;ALA A 292","H1N A 501 (-3.4A);H1N A 501 (-3.6A);None;H1N A 501 (-4.8A);H1N A 501 ( 3.9A)","0.37A","3cs9A-6ccfA:22.2","3cs9A-6ccfA:14.13"]]